Elixirgen Therapeutics
Baltimore, MD · Biotechnology · 13 employees
Elixirgen Therapeutics is a biotechnology company advancing its controllable self-replicating RNA technology to develop therapies for a broad spectrum of diseases, including rare diseases, aging-related disorders, and cancer. Elixirgen Therapeutics is located in the Science + Technology Park at Johns Hopkins in Baltimore.
Funding history
- Funding Round — $4.0M — Nov 2025
- Series seed — $3.6M — Apr 2025
- Series seed — $600K — Feb 2025
- Funding Round — $7.0M — Dec 2023
- Funding Round — $5.0M — Sep 2022
Recent signals
- Nov 13, 2025: Raised $4.0M
- Apr 09, 2025: Raised $3.6M in Series seed
- Feb 12, 2025: Raised $600K in Series seed
- Dec 01, 2023: Raised $7.0M
- Sep 29, 2022: Raised $5.0M
- Feb 18, 2021: Raised $4.2M
- Aug 17, 2020: Raised $5.7M
- Dec 02, 2019: Raised $5.7M
See plans & pricing → Track Elixirgen Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.